This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: